Akebia Therapeutics, Inc. (Nasdaq:Akba) He is One of the 10 best shares of health care for purchase, according to analysts. On June 2, the company stated that it had given options to buy a total of 137,000 shares from its joint shares to three newly appointed employees on May 30, 2025.
Yezry/Shutterstock.com
These options were given as materials urging every employee who is working with Akebia. The company stated that the grants were offered to each Nasdak base at Al Qaeda 5635 (c) (4). Also, the options exercise price is $ 3.03 per share, which is the company’s shared stock closing price in the history of the grant.
The stock options disappear over four years, with 25 % of the shares on the first anniversary of the date of the grant. The remaining 75 % will remain a chapter after that, provided that the new employee remains with Akebia. The options are the latest after Akebia was awarded 148,000 shares from their joint shares to eight newly appointed employees on April 30, 2025.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a biomedical pharmaceutical company that focuses on developing treatments related to kidney. It develops and sells two major producers: Aurlyxia, used to manage phosphorous levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and VAFSEO, which is a oral drug for anemia associated with CKD.
While we acknowledge the capabilities of AKBA as an investment, we believe that some artificial intelligence shares provide greater potential in the upward direction and carry less negative risks. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.
Read the following: Power stocks in Goldman Sachs: 10 shares for purchase and 10 best shares of Amnesty International for purchase, according to billionaire David.
Detection: Nothing.
https://media.zenfs.com/en/insidermonkey.com/e95b04fd80cf11753ca89ae0f933b98f
Source link